Concerto Biosciences has dosed the first subject in a Phase I trial of the three-stain live biotherapeutic product, ENS-002, ...

Atopic dermatitis is a chronic relapsing, pruritic, inflammatory skin disease. The latest in the detection of disease and its triggers, prognosis, treatment, prevention, and patient education is ...

Dermatology Nursing. 2006;18(6):531-542. Secondary prevention of atopic dermatitis involves avoiding and/or reducing the identifiable triggers in AD and maintaining a good skin care regimen.

Concerto Biosciences, a biotechnology company that leverages a powerful screening technology called kChip to rapidly discover microbial, prebiotic, and postbiotic product candidates, today announced ...

AnaptysBio’s drug candidates rosnilimab and ANB032 hold key trial results ahead. Find out why ANAB stock is impacted by ...

Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned biotech executives -- ...

Therefore, even individuals without childhood eczema may experience it later in life. Dr Grant has debunked the common ...

Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

Atopic dermatitis tends to develop in the first ... And they may require different treatment or management strategies. Because heat rash and eczema can look similar to each other, it’s not ...

Detailed price information for Inmed Pharmaceuticals Inc (INM-Q) from The Globe and Mail including charting and trades.

Aclaris stock surges on inking an exclusive license agreement with Biosion for global rights to two of the latter's pipeline candidates, BSI-045B and BSI-502.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...